NVP-CGM097 (CGM-097) |MDM2 inhibitor

NVP-CGM097 (CGM-097) |MDM2 inhibitor

NVP-CGM097 (CGM-097) is a potent and selective MDM2 inhibitor.

Product Name: NVP-CGM097 (CGM-097)|Cat No. DC9769|CAS: 1313363-54-0|Other names:CGM097; CGM-097; CGM 097; NVPCGM097; NVPCGM 097; NVPCGM-097|MW: 659.26|Molecule Formular: C38H47ClN4O4 |Purity>98%.

CGM097 is an orally bioavailable HDM2 (human homolog of double minute 2) antagonist with potential antineoplastic activity. Upon oral administration, p53/HDM2 interaction inhibitor CGM097 inhibits the binding of the HDM2 protein to the transcriptional activation domain of the tumor suppressor protein p53. By preventing this HDM2-p53 interaction, the proteosome-mediated enzymatic degradation of p53 is inhibited, which may result in the restoration of p53 signaling and, thus, the p53-mediated induction of tumor cell apoptosis. HDM2, a zinc finger nuclear phosphoprotein, is a negative regulator of the p53 pathway, often overexpressed in cancer cells and has been implicated in cancer cell proliferation and survival.